Invuity, Inc. has raised a $25 million Series D round of financing to expand the development, manufacturing and commercialization of the company's advanced medical devices. The financing was led by Valence Advantage Life Sciences Fund II, which is run by the team that also manages the Caxton Advantage Life Sciences Fund. Eric Roberts from Valence Advantage will join Invuity's Board of Directors.